Annexon, Inc. SEC Filings

Annexon reported first-quarter 2026 results showing a narrower loss and solid liquidity while advancing its late-stage pipeline. Net loss was $44.1 million versus $54.4 million a year earlier, as research and development spending fell to $35.8 million and general and administrative expenses rose modestly to $10.3 million.

Cash, cash equivalents and short-term investments totaled $225.0 million, and management believes this will fund operations into the second half of 2027. The company continues to focus on tanruprubart for Guillain-Barré Syndrome, vonaprument for geographic atrophy in dry AMD, and oral ANX1502 for autoimmune conditions, while maintaining additional capital access through at-the-market equity programs.

Annexon, Inc. reported first quarter 2026 results and highlighted progress across its late-stage neuroinflammatory pipeline. The company recorded a net loss of $44.1 million, or $0.23 per share, for the quarter ended March 31, 2026, compared with a net loss of $54.4 million, or $0.37 per share, a year earlier.

Research and development expenses were $35.8 million, down from $48.2 million, primarily reflecting spending on the Phase 3 ARCHER II trial of vonaprument in geographic atrophy and regulatory activities for tanruprubart in Guillain-Barré syndrome. General and administrative expenses were $10.3 million, up from $9.2 million, mainly due to consulting and professional services.

Annexon reported cash, cash equivalents and short-term investments of approximately $225 million as of March 31, 2026, and expects this to fund operations and planned milestones into the second half of 2027. Key upcoming catalysts include topline Phase 3 vonaprument data in geographic atrophy in the fourth quarter of 2026, a planned Biologics License Application submission for tanruprubart in Guillain-Barré syndrome in 2026, and proof-of-concept data for oral C1 inhibitor ANX1502 in 2026.

Annexon, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on four key items: electing two Class III directors, ratifying KPMG LLP as auditor for 2026, holding an advisory vote on executive pay, and approving a significant increase in authorized common stock.

The company currently has 300,000,000 authorized common shares and 162,507,278 shares outstanding as of April 13, 2026. It proposes raising authorized common shares to 500,000,000 to support future capital raising, strategic transactions, and equity incentives, noting only 24,753,021 shares remain unissued and unreserved. As of the same date, substantial blocks of shares are reserved for equity plans, warrants, and at-the-market sales programs. The board recommends voting “For” all four proposals.

Annexon, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on June 11, 2026. The Board asks stockholders to vote on: election of two Class III directors, ratification of KPMG as auditor, an advisory say-on-pay vote, and an amendment to increase authorized common stock from 300,000,000 to 500,000,000 shares. The record date for voting is April 13, 2026 and there were 162,507,278 shares outstanding on that date. The proxy includes disclosure of director nominees, board committees, executive officers, 2025 executive compensation, equity awards and the Board’s recommendation to vote “For” each proposal.

Annexon, Inc. director William H. Carson reported buying additional company stock. On April 10, 2026, he made an open-market purchase of 8,000 shares of common stock at $6.20 per share, bringing his direct holdings to 70,405 shares of Annexon common stock.

The filing notes that this transaction was executed under Carson’s Rule 10b5-1 trading plan, adopted on December 8, 2025, indicating the trade was pre-scheduled rather than a discretionary market-timing decision.

Annexon, Inc. is a clinical-stage biopharma company developing targeted immunotherapies for complement‑mediated neuroinflammatory diseases of the body, brain and eye.

The company’s late-stage programs include tanruprubart for Guillain‑Barré Syndrome, vonaprument for geographic atrophy in dry AMD, and oral candidate ANX1502 for autoimmune conditions, all built around inhibition of the classical complement pathway, particularly C1q and C1s.

Annexon reports it will need substantial additional financing, has no approved products, and is advancing multiple precision-medicine programs while relying on third‑party manufacturers and extensive patent protection for its platform and pipeline.

Annexon, Inc. furnished an update on its fourth quarter and full-year 2025 results alongside progress across its late-stage neuroinflammatory pipeline. The company is advancing three key programs: vonaprument for geographic atrophy, tanruprubart for Guillain-Barré syndrome, and oral C1 inhibitor ANX1502 for autoimmune disease.

Vonaprument’s pivotal Phase 3 ARCHER II trial in geographic atrophy has completed enrollment, with topline data expected in the fourth quarter of 2026. Tanruprubart has an MAA filed in Europe for GBS, with the US/EU FORWARD study intended to support a planned BLA submission in 2026.

Annexon reported cash, cash equivalents and short-term investments of $238.3 million as of December 31, 2025, and expects its operating runway to extend into the second half of 2027. For 2025, R&D expenses were $184.7 million and G&A expenses were $31.7 million, leading to a net loss attributable to common stockholders of $208.5 million, or $1.34 per share.

Annexon Inc: Amendment to a Schedule 13G filed by The Vanguard Group reports 0 shares beneficially owned and 0% of common stock following an internal realignment effective January 12, 2026. The amendment states certain Vanguard subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538.

The filing is signed by Vanguard's Head of Global Fund Administration and lists Vanguard's Malvern, PA address; it clarifies that Vanguard and its managed accounts have the right to receive dividends or proceeds but that no single other person holds more than 5% of the class.